Rigel to Present at the Jefferies Global Healthcare Conference

5/28/25 8:05:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RIGL alert in real time by email

SOUTH SAN FRANCISCO, Calif., May 28, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 12:50 p.m. ET in New York, NY.

To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.

About Rigel

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.

Contact for Investors & Media:

Investors:

Rigel Pharmaceuticals, Inc.

650.624.1232

[email protected]

Media:

David Rosen

Argot Partners

646.461.6387

[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-to-present-at-the-jefferies-global-healthcare-conference-302466594.html

SOURCE Rigel Pharmaceuticals, Inc.

Get the next $RIGL alert in real time by email

Date

Price Target

Rating

Analyst

4/3/2023

$2.00

Neutral

Piper Sandler

6/9/2022

Buy → Neutral

Citigroup

6/8/2022

$7.00 → $1.00

Overweight → Neutral

Piper Sandler

6/8/2022

$6.00 → $1.00

Overweight → Neutral

Cantor Fitzgerald

3/23/2022

$4.00

Neutral

B. Riley Securities

Rigel to Present at the Jefferies Global Healthcare Conference

Chat with this insight

Recent Analyst Ratings for
$RIGL

$RIGL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Rigel Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Rigel Pharmaceuticals Inc.

SEC Form SC 13G filed by Rigel Pharmaceuticals Inc.

$RIGL
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Wasman Jane was granted 2,500 shares, increasing direct ownership by 25% to 12,500 units (SEC Form 4)

Director Ali-Jackson Kamil was granted 2,500 shares, increasing direct ownership by 36% to 9,375 units (SEC Form 4)

Director Moos Walter H was granted 2,500 shares, increasing direct ownership by 24% to 12,722 units (SEC Form 4)

$RIGL
SEC Filings

Rigel Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

Rigel Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Rigel Pharmaceuticals Inc.

$RIGL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Piper Sandler resumed coverage on Rigel Pharma with a new price target

Rigel Pharma downgraded by Citigroup

Rigel Pharma downgraded by Piper Sandler with a new price target

$RIGL
Leadership Updates

Live Leadership Updates

Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

$RIGL
Press Releases

Fastest customizable press release news feed in the world

$RIGL
Financials

Live finance-specific insights